BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg RJ, Pajak T, Salter M, Benson AB 3rd. Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 1999;43:517-523. [PMID: 10078631 DOI: 10.1016/s0360-3016(98)00463-5] [Cited by in Crossref: 91] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Nehlsen AD, Lehrer EJ, Resende-Salgado L, Rosenzweig KE, Buckstein M. Comparison of Pathologic Complete Response Rates and Oncologic Outcomes in Patients With Surgically Resectable Esophageal Cancer Treated With Neoadjuvant Chemoradiation to 50.4 Gy vs 41.4 Gy. Cureus 2021;13:e19233. [PMID: 34877210 DOI: 10.7759/cureus.19233] [Reference Citation Analysis]
2 Zhang L, Song Y, Jiang N, Huang Y, Dong B, Li W, He Y, Chen Y, Liu H, Yu R. Efficacy and safety of anti-epidermal growth factor receptor agents for the treatment of oesophageal cancer: a systematic review and meta-analysis. BMJ Open 2021;11:e046352. [PMID: 33753446 DOI: 10.1136/bmjopen-2020-046352] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Pang Q, Wei X, Zhang W, Zhang T, Chen X, Dong J, Wei H, Er P, Zhao J, Han D, Guo Z, Lei T, Du Q, Guan Y, Wang J, Zhao L, Wang J, Yuan Z, Song Y, Liu N, Wang P. Annual report of the esophageal cancer radiation group of the Department of Radiotherapy, Tianjin Medical University Cancer Institute & Hospital. Ann Transl Med 2020;8:1156. [PMID: 33241005 DOI: 10.21037/atm-20-4064] [Reference Citation Analysis]
4 Lin CH, Hung TM, Chang YC, Hsieh CH, Shih MC, Huang SM, Yang CK, Chang CF, Chan SC, Yap WK. Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy. Cancers (Basel) 2020;12:E607. [PMID: 32155748 DOI: 10.3390/cancers12030607] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Haque W, Butler EB, Teh BS. Neoadjuvant radiation therapy for esophageal cancer: is a higher dose better? J Thorac Dis 2019;11:5631-4. [PMID: 32030286 DOI: 10.21037/jtd.2019.11.77] [Reference Citation Analysis]
6 Jin X, Zheng X, Chen D, Jin J, Zhu G, Deng X, Han C, Gong C, Zhou Y, Liu C, Xie C. Prediction of response after chemoradiation for esophageal cancer using a combination of dosimetry and CT radiomics. Eur Radiol. 2019;29:6080-6088. [PMID: 31028447 DOI: 10.1007/s00330-019-06193-w] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
7 Chen M, Liu P, Chen Y, Chen Z, Shen M, Liu X, Li X, Lin Y, Yang R, Ni W, Zhou X, Zhang L, Tian Y, Chen J. Primary tumor regression patterns in esophageal squamous cell cancer treated with definitive chemoradiotherapy and implications for surveillance schemes. Cancer Manag Res. 2019;11:3361-3369. [PMID: 31114372 DOI: 10.2147/cmar.s198524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Semenkovich TR, Samson PP, Hudson JL, Subramanian M, Meyers BF, Kozower BD, Kreisel D, Patterson GA, Robinson CG, Bradley JD, Puri V. Induction Radiation Therapy for Esophageal Cancer: Does Dose Affect Outcomes? Ann Thorac Surg 2019;107:903-11. [PMID: 30444988 DOI: 10.1016/j.athoracsur.2018.09.064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Zhu W, Zhang Y, Kong L, Huang Y, Zheng J, Wang R, Li M, Yu J. 18F-fluorodeoxyglucose positron emission tomography predicts lymph node responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma patients. Onco Targets Ther 2018;11:4345-53. [PMID: 30100740 DOI: 10.2147/OTT.S160456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Li J, Gong Y, Diao P, Huang Q, Wen Y, Lin B, Cai H, Tian H, He B, Ji L, Guo P, Miao J, Du X. Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis. Radiat Oncol 2018;13:12. [PMID: 29357883 DOI: 10.1186/s13014-018-0958-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
11 Luo Y, Mao Q, Wang X, Yu J, Li M. Radiotherapy for esophageal carcinoma: dose, response and survival. Cancer Manag Res 2018;10:13-21. [PMID: 29343986 DOI: 10.2147/CMAR.S144687] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
12 Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A, Chakravarthy AB, Anker CJ, Thakrar H, Horiba N, Dubey A, Greenberger JS, Raben A, Giguere J, Roof K, Videtic G, Pollock J, Safran H, Crane CH. Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial. JAMA Oncol 2017;3:1520-8. [PMID: 28687830 DOI: 10.1001/jamaoncol.2017.1598] [Cited by in Crossref: 81] [Cited by in F6Publishing: 79] [Article Influence: 16.2] [Reference Citation Analysis]
13 Zhu Y, Zhang W, Li Q, Li Q, Qiu B, Liu H, Liu M, Hu Y. A Phase II Randomized Controlled Trial: Definitive Concurrent Chemoradiotherapy with Docetaxel Plus Cisplatin versus 5-Fluorouracil plus Cisplatin in Patients with Oesophageal Squamous Cell Carcinoma. J Cancer 2017;8:3657-66. [PMID: 29151952 DOI: 10.7150/jca.20053] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
14 Luo LL, Xi M, Yang YD, Li QQ, Zhao L, Zhang P, Liu SL, Liu MZ. Comparative Outcomes of Induction Chemotherapy Followed By Definitive Chemoradiotherapy versus Chemoradiotherapy Alone In Esophageal Squamous Cell Carcinoma. J Cancer 2017;8:3441-7. [PMID: 29151927 DOI: 10.7150/jca.21131] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kumaran D, John S, Isiah R, Das S. Management of Locally Advanced Carcinoma Oesophagus with Radiation/Chemoradiation: Single Institute Experience. J Gastrointest Cancer 2016;47:313-7. [PMID: 27146042 DOI: 10.1007/s12029-016-9825-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Safaei AM, Ghalehtaki R, Khanjani N, Farazmand B, Babaei M, Esmati E. High-dose-rate intraluminal brachytherapy prior to external radiochemotherapy in locally advanced esophageal cancer: preliminary results. J Contemp Brachytherapy 2017;9:30-5. [PMID: 28344601 DOI: 10.5114/jcb.2017.65147] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Cho JH, Kim TN. Long-term survival after concurrent chemoradiation therapy for esophageal cancer with tracheal invasion. Korean J Intern Med 2015;30:931-3. [PMID: 26552472 DOI: 10.3904/kjim.2015.30.6.931] [Reference Citation Analysis]
18 Zhu LL, Yuan L, Wang H, Ye L, Yao GY, Liu C, Sun NN, Li XJ, Zhai SC, Niu LJ. A Meta-Analysis of Concurrent Chemoradiotherapy for Advanced Esophageal Cancer. PLoS One. 2015;10:e0128616. [PMID: 26046353 DOI: 10.1371/journal.pone.0128616] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
19 Tamandl D, Gore RM, Fueger B, Kinsperger P, Hejna M, Paireder M, Haug A, Schoppmann SF, Ba-Ssalamah A. Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer. Eur Radiol 2016;26:311-21. [PMID: 26040648 DOI: 10.1007/s00330-015-3860-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
20 Jeong Y, Kim JH. WITHDRAWN: Multimodality treatment for locally advanced esophageal cancers. Gastrointestinal Intervention 2014. [DOI: 10.1016/j.gii.2014.09.003] [Reference Citation Analysis]
21 Roeder F, Nicolay NH, Nguyen T, Saleh-Ebrahimi L, Askoxylakis V, Bostel T, Zwicker F, Debus J, Timke C, Huber PE. Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer. Radiat Oncol 2014;9:191. [PMID: 25175056 DOI: 10.1186/1748-717X-9-191] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
22 Meng MB, Jiang C, Tian LJ, Liu CL, Zhuang HQ, Chen ZJ, Song YC, Wang J, Pang QS, Zhao LJ, Yuan ZY, Wang P. Late course accelerated hyperfractionation radiotherapy for locally advanced esophageal squamous cell carcinoma. Thorac Cancer 2013;4:174-85. [PMID: 28920199 DOI: 10.1111/j.1759-7714.2012.00166.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Schweigert M, Dubecz A, Stein HJ. Oesophageal cancer--an overview. Nat Rev Gastroenterol Hepatol. 2013;10:230-244. [PMID: 23296250 DOI: 10.1038/nrgastro.2012.236] [Cited by in Crossref: 55] [Cited by in F6Publishing: 63] [Article Influence: 6.1] [Reference Citation Analysis]
24 Miura A, Honda M, Izumi Y, Kato T, Ryoutokuji T, Kuga G, Karasawa K, Momma K, Fujiwara J, Egashira H, Yoshida M. Induction chemotherapy followed by chemoradiotherapy for T4M0 esophageal cancer. Esophagus 2011;8:31-7. [DOI: 10.1007/s10388-011-0255-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Tachimori Y. Role of salvage esophagectomy after definitive chemoradiotherapy. Gen Thorac Cardiovasc Surg 2009;57:71-8. [PMID: 19214447 DOI: 10.1007/s11748-008-0337-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
26 Tougeron D, Di Fiore F, Thureau S, Berbera N, Iwanicki-Caron I, Hamidou H, Paillot B, Michel P. Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer 2008;99:1586-92. [PMID: 19002180 DOI: 10.1038/sj.bjc.6604749] [Cited by in Crossref: 71] [Cited by in F6Publishing: 82] [Article Influence: 5.1] [Reference Citation Analysis]
27 Fiore FD, Lecleire S, Rigal O, Galais MP, Soussan EB, David I, Paillot B, Jacob JH, Michel P. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12(26): 4185-4190 [PMID: 16830371 DOI: 10.3748/wjg.v12.i26.4185] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.0] [Reference Citation Analysis]
28 Vandenbroucke F, Lozac'h P, Metges JP, Malhaire JP. [Results of surgical resection of squamous cells carcinoma of the oesophagus with or without preoperative radiochemotherapy: comparative and retrospective study]. Ann Chir 2004;129:583-8. [PMID: 15581819 DOI: 10.1016/j.anchir.2004.10.001] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
29 Ilson DH. New developments in the treatment of esophageal cancer. Curr Oncol Rep 2002;4:213-21. [PMID: 11937011 DOI: 10.1007/s11912-002-0018-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
30 Lord RV. Optimal treatment for localized esophageal cancer still uncertain. Am J Gastroenterol 2000;95:305-7. [PMID: 10638607 DOI: 10.1111/j.1572-0241.2000.01738.x] [Reference Citation Analysis]